Psychiatry Investig.
2013 Dec;10(4):417-420.
Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases
- Affiliations
-
- 1Department of Psychiatry, Medical Faculty, Namik Kemal University, Tekirdag, Turkey.
- 2Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan. dr.fuge@hotmail.com
Abstract
- Fluvoxamine is a selective serotonin reuptake inhibitor that is approved for psychiatric disorders such as major depressive episodes and obsessive-compulsive disorder. Beside inhibition of serotonin reuptake, fluvoxamine is also a potent agonist of endoplasmic reticulum (ER) protein sigma-1 receptors, which play a role in the pathophysiology of a number of psychiatric and neurodegenerative disorders. This report presents beneficial effects of sigma-1 agonist fluvoxamine on hyperkinetic movement disorders such as tardive dyskinesia and tardive akathisia. Fluvoxamine might be a novel treatmet approach in the treatment of hyperkinetic movement disorders.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Low Dose Olanzapine Induced Tardive Dyskinesia: A Case Report
- Association of Tardive Dyskinesia with Cognitive Deficit in Schizophrenia
- Successful Management of Tardive Dyskinesia with Quetiapine and Clonazepam in a Patient of Schizophrenia with Type 2 Diabetes Mellitus
- Tardive Dyskinesia: Treatment with Aripiprazole
- A Case on Risperidone-Induced Tardive Dyskinesia
